-
Pharmacists’ Engagement With Pharmaceutical Care in Pakistan: Insights From a Cross-Sectional Survey on Knowledge, Attitudes, Practices, and Barriers
Sep 9, 2025, 16:22 PM -
France and the Challenge of High-Cost Innovative Drug Expenditures in Hospitals
Sep 9, 2025, 16:22 PM -
Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies
Sep 9, 2025, 16:22 PM -
Comparing Countries’ Time to Treatment Initiation: A Study of Metastatic Breast Cancer in Austria and the United States
Sep 9, 2025, 16:22 PM -
Evolution of Health Technology Assessment (HTA) in India: A Scoping Review and Thematic Analysis
Sep 9, 2025, 16:22 PM -
Budget Impact of Introducing an Omalizumab Biosimilar in 23 European Countries
Sep 9, 2025, 16:22 PM -
International Reference Pricing (IRP) Analysis for Original Medicines in Türkiye in 2024
Sep 9, 2025, 16:22 PM -
Beyond RCTs: The Role of Patient Perspectives and Nontraditional Evidence in HTA Decisions for Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC)
Sep 9, 2025, 16:22 PM -
Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data
Sep 9, 2025, 16:22 PM -
Bridging Systemic Access Gaps for Cancer Medicines: A Policy Perspective From the Republic of Moldova
Sep 9, 2025, 16:22 PM -
Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025
Sep 9, 2025, 16:22 PM -
The SISAQOL-IMI Recommendations on Standardizing the Use of Thresholds for Interpretation of Patient-Reported Outcome Results in Cancer Clinical Trials
Sep 9, 2025, 16:22 PM -
Modeling Framework for Assessing Cost-Effectiveness of New Treatments in Chronic Kidney Disease
Sep 9, 2025, 16:22 PM -
The Importance and Recognition of Hypo and Hyperkalemia in Prehospital Care
Sep 9, 2025, 16:22 PM -
Factors Associated With Response to Patient-Reported Outcome Measures: A Systematic Review of Systematic Reviews and Meta-analyses
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective
Sep 9, 2025, 16:22 PM -
Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach
Sep 9, 2025, 16:22 PM -
The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis
Sep 9, 2025, 16:22 PM -
Pricing Implications of Subcutaneous Reformulations Following Intravenous Launches: A Multicountry Analysis
Sep 9, 2025, 16:22 PM
